Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Pfizer's stock is cheap but faces operational challenges. Analyze its valuation and performance to make informed investment ...

Vaxcyte plunges 56% even though its VAX-24 pneumonia vaccine shows positive phase two results in infants. Read more here.

Representative Rob Bresnahan, Jr. of Pennsylvania recently made headlines—not for legislation, but for investing between ...

Investing.com -- Moderna (NASDAQ: MRNA) shares dropped 13% pre-open on Monday as investors reacted to the weekend news that the U.S. Food and Drug Administration’s (FDA) top vaccine official, Dr.

Dziubinski: All right, we’ve arrived at everyone’s favorite part of the show: this week’s stock picks. Now these three stocks ...

Vaxcyte's VAX-24 Phase 2 trial showed a safety profile similar to PCV20, with strong immune responses and no serious ...

TD Cowen analyst Yaron Werber maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $389.00. The company’s ...

Redburn Atlantic initiated coverage of Alnylam with a Buy rating and $353 price target Therapeutic options for patients with transthyretin ...

US stocks tumbled to their lowest levels in over six months as worries over new tariffs weighed on investor sentiment. With ...

US benchmark equity indexes were lacking direction on Monday as investors await announcement of the reciprocal tariffs this week. The Nasdaq Composite fell 0.1% to 17,299.3, while the S&P 500 ...

At close: March 28 at 4:00:02 PM EDT ...